Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesKazia Therapeutics Ltd ADR

Kazia Therapeutics Ltd ADR

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.05 USD 0.03 ( 0.37%)
Last update at 2026-11-03T21:00:00Z
VOLUME
112216
Market Cap
4.88M

Momentum Score

…

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.93
Low
8.23
High
52 Week Price Range
2.86
Low
79.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Kazia Therapeutics is a clinical-stage oncology company developing therapies for brain cancers; its lead candidate, paxalisib, is an oral small-molecule PI3K/Akt/mTOR pathway inhibitor designed to cross the blood–brain barrier. Long-term growth drivers include favorable clinical trial outcomes, regulatory approvals, and successful commercialization or licensing of lead programs, which could support broader use in glioblastoma and brain metastases.

Material risks include high clinical and regulatory uncertainty, dependence on a single lead asset, and the likelihood of additional capital raising that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.02
Dividend Yield
-
Revenue TTM
2.48M
Revenue Per Share
4.71
Gross Profit TTM
2.48M
Debt / Equity
-0.06
ROE
-2634.33%
Net Debt
-1.02M
ROCE
572.74%
Diluted EPS TTM
-32.64

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -20.74M -25.02M -8.91M -12.77M -10.57M
Minority interest - - - - 0.00M
Net income -20.47M -24.65M -8.42M -12.47M -10.27M
Selling general administrative 8.58M 4.51M 7.02M 3.69M 3.79M
Selling and marketing expenses - 0.13M - - -
Gross profit - 0.00M 15.18M 0.00M 0.00M
Reconciled depreciation 1.87M 1.95M 1.26M 1.08M 1.08M
Ebit -24.12M -26.70M -3.81M -12.53M -8.38M
Ebitda -27.53M -24.74M -2.54M -11.44M -7.30M
Depreciation and amortization -3.41M 1.95M 1.26M 1.08M 1.08M
Non operating income net other - - - - 0.00M
Operating income -24.12M -26.70M -3.81M -12.53M -8.38M
Other operating expenses 24.15M 24.88M 21.56M 13.16M 10.25M
Interest expense - 0.00M 5.10M 0.24M 2.19M
Tax provision -0.27M -0.37M -0.48M -0.30M -0.30M
Interest income 0.02M 0.00M 0.04M 0.07M 0.10M
Net interest income 0.02M 0.00M 0.04M 0.07M 0.10M
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense -0.27M -0.37M -0.48M -0.30M -0.30M
Total revenue 0.00M 0.00M 15.18M 0.00M 0.00M
Total operating expenses 24.15M 24.88M 21.56M 13.16M 10.25M
Cost of revenue - - - - 0.00M
Total other income expense net 3.39M 1.68M -5.10M -0.24M -2.19M
Discontinued operations - - - - 0.00M
Net income from continuing ops -20.47M -24.65M -8.42M -12.47M -10.27M
Net income applicable to common shares -20.47M -24.65M -8.42M -12.47M -10.27M
Preferred stock and other adjustments - - - - 0.00M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 21.59M 28.09M 34.96M 58.09M 23.06M
Intangible assets 15.40M 17.27M 20.05M 22.00M 12.41M
Other current assets 0.59M 3.79M 0.20M 1.73M 0.69M
Total liab 31.60M 16.03M 16.32M 20.24M 8.94M
Total stockholder equity -10.02M 12.05M 18.64M 37.85M 14.12M
Other current liab 20.61M 0.75M 3.16M 6.43M 3.37M
Common stock 101.64M 97.45M 84.48M 80.29M 48.78M
Capital stock 101.64M 97.45M 84.48M 80.29M 48.78M
Retained earnings -115.13M -89.08M -68.25M -44.20M -36.19M
Other liab - 8.47M 11.64M 11.91M 3.87M
Other assets - 0.04M 7.30M 6.69M -
Cash 1.66M 5.24M 7.36M 27.59M 8.76M
Total current liabilities 25.80M 7.57M 4.69M 8.33M 5.07M
Current deferred revenue - 4.16M - - -
Net debt -1.02M -3.44M -7.36M -27.59M -8.76M
Short term debt 0.63M 1.80M - - -
Short long term debt 0.63M 1.80M - - -
Short long term debt total 0.63M 1.80M - - -
Other stockholder equity 0.00M 4.42M 0.00M 0.46M 0.46M
Total current assets 6.14M 10.77M 7.61M 29.39M 10.65M
Long term investments - - - - 0.00M
Net tangible assets - -5.22M -1.41M 15.85M 1.72M
Net receivables 0.13M 0.11M 0.05M 0.08M 1.19M
Accounts payable 4.55M 0.86M 1.52M 1.89M 1.69M
Accumulated other comprehensive income 3.48M -0.74M 2.41M 1.30M 1.07M
Common stock total equity - - - 80.29M 48.78M
Non currrent assets other 0.04M 0.04M 7.30M 6.69M -
Non current assets total 15.44M 17.31M 27.35M 28.70M 12.41M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.00M -2.36M 0.00M 0.00M 2.36M
Change to liabilities 0.30M -1.86M 0.53M 1.42M -0.71M
Total cashflows from investing activities - -2.36M -2.36M -2.36M 2.36M
Net borrowings - - - - 0.00M
Total cash from financing activities 12.97M 3.73M 28.11M 12.14M 3.82M
Change to operating activities 0.58M 1.76M -1.09M -0.11M 0.37M
Net income -20.46M -24.65M -8.42M -12.47M -10.27M
Change in cash -2.12M -20.23M 18.82M 3.33M -0.52M
Begin period cash flow 7.36M 27.59M 8.76M 5.43M 5.96M
End period cash flow 5.24M 7.36M 27.59M 8.76M 5.43M
Total cash from operating activities -15.16M -22.76M -9.11M -8.81M -6.71M
Issuance of capital stock 12.97M 3.73M 28.11M 12.14M 3.82M
Depreciation 1.87M 1.95M 1.26M 1.08M 1.08M
Other cashflows from investing activities - -2.36M -2.36M -2.36M 2.36M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables 3.45M -0.01M -5.03M 0.36M 0.82M
Sale purchase of stock - - - - 3.82M
Other cashflows from financing activities -0.00M -2.36M -1.67M -0.83M 2.36M
Change to netincome -0.89M 0.04M 3.64M 0.90M 2.12M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change receivables - - - - 0.00M
Cash flows other operating - - - - 0.00M
Exchange rate changes - - - - 0.00M
Cash and cash equivalents changes - - - - 0.00M
Change in working capital 4.33M -0.10M -5.59M 1.67M 0.35M
Stock based compensation 1.16M 1.68M 0.64M 0.26M 0.25M
Other non cash items -2.10M -1.64M 2.57M 0.47M 0.06M
Free cash flow -15.16M -22.76M -9.11M -8.81M -6.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
KZIA
Kazia Therapeutics Ltd ADR		 0.03
0.37%		 8.05 - - 1.97 3.09 2.86 -0.71
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Kazia Therapeutics Ltd ADR

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Three International Towers, Sydney, NSW, Australia, 2000

61 2 9472 4101

https://www.kaziatherapeutics.com

Name Title Year Born
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( CEO, MD & Exec. Director 1973
Ms. Karen R. Krumeich Chief Financial Officer 1954
Dr. John E. Friend II, M.D. Chief Medical Officer 1970
Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD Company Sec. 1959
Dr. John Edwin Friend II, M.D. CEO, MD & Director 1970
Ms. Gabrielle Heaton BBUS (ACC), CPA Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer NA
Ms. Anna Sandham Company Secretary NA
Ms. Elissa C. Hansen ACSA, B.Com., B.Comm, FCIS, Gad Dip ACG, GAI, GAIC Company Secretary 1973
Mr. Jeffrey Bonacorda VP of Finance & Controller NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…